Indraprastha Medical Corporation Limited (INDRAMEDCO) AI Stock Analysis

• Market Cap: ₹42.11B
• Dividend Yield: 0.98%
• Average Volume (3M): 18.47K
• Price to Earnings (P/E): 25.1
• Beta (1Y): 1.10
• Revenue Growth: 6.80%
• EPS Growth: 21.28%
• Country: IN
• Employees: 2,977
• Sector: Healthcare
• Sector Strength: 48
• Industry: Medical - Care Facilities
• EPS (TTM): 1.10
• Shares Outstanding: 91,673,000
• 10 Day Avg. Volume: 11,913
• 30 Day Avg. Volume: 18,471
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹489.00
• Price Target Upside: 6.44% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 67 Neutral
• Price Target: ₹494.00 ▲(7.53% Upside)

Indraprastha Medical Corporation Limited exhibits strong financial performance with consistent revenue growth and profitability, which is the most significant factor in the score. However, technical indicators suggest short-term bearish momentum, and the valuation indicates the stock is fairly valued. Attention to cash management is advised.

Indraprastha Medical Corporation Limited Business Overview & Revenue Model

Company Description

Indraprastha Medical Corporation Limited (INDRAMEDCO) operates as a prominent healthcare provider in India. It manages and runs multi-specialty hospitals that offer a wide range of medical services, including diagnostics, treatment, and surgical procedures. The company is renowned for its state-of-the-art healthcare facilities and a team of experienced medical professionals, focusing on delivering high-quality patient care across various medical disciplines.

How the Company Makes Money

Indraprastha Medical Corporation Limited generates revenue primarily through the provision of healthcare services. The company's key revenue streams include patient fees for consultations, medical treatments, and surgical procedures. Additionally, it earns income from diagnostic services, outpatient services, and emergency care. The company may also engage in partnerships with insurance providers to facilitate patient access to its services, thereby broadening its customer base and ensuring a steady stream of revenue. Furthermore, ancillary services such as pharmacy sales and laboratory tests contribute to the company's overall earnings.

Indraprastha Medical Corporation Limited Financial Statement Overview

Summary

Indraprastha Medical Corporation Limited exhibits strong financial health with consistent revenue growth and profitability. The balance sheet reflects low leverage and solid equity. However, attention to cash management is advised due to recent declines in cash reserves. Overall, the financial statements indicate a well-managed company with potential for continued growth.

Income Statement

Indraprastha Medical Corporation Limited has demonstrated strong revenue growth over the years, increasing from 5,960 million INR in 2021 to 13,563 million INR in 2025. The gross profit margin has improved significantly, indicating strong operational efficiency, and the net profit margin has also shown consistent improvement, reaching 11.87% in 2025. The EBIT and EBITDA margins reflect healthy profitability, contributing to a robust income statement performance.

Balance Sheet

The company maintains a solid equity position with a debt-to-equity ratio consistently low, indicating low leverage risk. Return on equity has improved, reflecting efficient use of equity capital. The equity ratio is strong, showing financial stability; however, the decrease in cash and cash equivalents from 2024 to 2025 indicates potential liquidity considerations.

Cash Flow

The cash flow statements reveal stable operational cash flows, though there was a decline in free cash flow in 2025 compared to the previous year. The free cash flow to net income ratio is healthy, suggesting effective cash generation relative to profit. However, the decline in operating cash flow in 2025 needs monitoring to ensure continued liquidity.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2022	Dec 2022	Dec 2021
Income Statement
Total Revenue	13.56B	13.56B	12.45B	8.62B	10.99B	5.96B
Gross Profit	4.71B	4.94B	4.54B	4.79B	6.25B	3.47B
EBITDA	2.61B	2.44B	2.07B	1.17B	1.61B	409.48M
Net Income	1.61B	1.61B	1.24B	586.20M	861.50M	23.30M
Balance Sheet
Total Assets	8.52B	8.52B	7.23B	4.62B	5.55B	4.32B
Cash, Cash Equivalents and Short-Term Investments	3.22B	3.22B	2.28B	707.90M	1.36B	296.10M
Total Debt	327.60M	327.60M	339.50M	53.10M	24.80M	78.18M
Total Liabilities	2.55B	2.55B	2.45B	1.36B	1.76B	1.59B
Stockholders Equity	5.97B	5.97B	4.78B	3.25B	3.79B	2.73B
Cash Flow
Free Cash Flow	0.00	1.20B	1.31B	418.10M	998.90M	69.35M
Operating Cash Flow	0.00	1.57B	2.00B	712.90M	1.44B	278.98M
Investing Cash Flow	0.00	-1.11B	-1.58B	-511.00M	-1.08B	-201.62M
Financing Cash Flow	0.00	-458.80M	-323.80M	-33.70M	-260.40M	-31.47M

Indraprastha Medical Corporation Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 459.40
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDRAMEDCO, the sentiment is Negative. The current price of 459.4 is below the 20-day moving average (MA) of 460.57, below the 50-day MA of 460.52, and above the 200-day MA of 439.18, indicating a neutral trend. The MACD of -0.61 indicates Positive momentum. The RSI at 45.83 is Neutral, neither overbought nor oversold. The STOCH value of 38.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:INDRAMEDCO.

Indraprastha Medical Corporation Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PFIZER	73 Outperform	₹259.10B	32.04		0.62%	4.35%	32.89%
CONCORDBIO	71 Outperform	₹184.64B	51.85		0.50%	14.49%	13.70%
INDRAMEDCO	67 Neutral	₹42.11B	25.12		0.98%	6.80%	21.28%
GLAXO	65 Neutral	₹474.25B	49.91		1.93%	6.65%	48.47%
METROPOLIS	64 Neutral	₹112.28B	73.41		0.71%	12.86%	10.42%
BIOCON	61 Neutral	₹479.53B	112.11		0.14%	6.80%	-75.66%
Sector *	51 Neutral	$7.78B	-0.06	-39.91%	2.29%	21.32%	-1.82%